The 1999 WHO-ISH guidelines for the management of hypertension - New targets, new treatment and a comprehensive approach to total cardiovascular risk reduction

Blood Pressure

Volumn 8, Issue SUPPL. 1, 1999, Pages 3-5

  Hansson, Lennart ^a   Hedner, Thomas ^a   Himmelman, Anders ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HUMAN; HYPERTENSION; MEDICAL SOCIETY; PRACTICE GUIDELINE; RISK; RISK FACTOR; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY RISK; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN TISSUE; META ANALYSIS; PRIORITY JOURNAL; RISK MANAGEMENT; SYSTOLIC HYPERTENSION;

HUMANS; HYPERTENSION; PRACTICE GUIDELINES; RISK; RISK FACTORS; SOCIETIES, MEDICAL; WORLD HEALTH ORGANIZATION;

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CANDESARTAN HEXETIL; FELODIPINE; HYDROCHLOROTHIAZIDE; LOSARTAN;

EID: 47249140654     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037059943973312     Document Type: Article

References (14)

1. Zanchetti A. A re-examination of stepped-care: a retrospective and a prospective. J Cardiovasc Pharmacol 1985; 7 (suppl 2): S126-S131. (Pubitemid 15174517)
2. Opie LH. Individualised selection of antihypertensive therapy. Drugs 1993; 46 (suppl 2): 142-148. (Pubitemid 24037883)
3. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
4. World Health Organization/International Society of Hypertension Fifth Mild Hypertension Conference. The 1989 guidelines for the management of mild hypertension. Memorandum from a WHO-ISH meeting. J Hypertens 1989; 7: 689-693.
5. Zanchetti A, Chalmers J, Arakawa K, Gyarfas I, Hamet P, Hansson L, Julius S, MacMahon S, Mancia G, Ménard J, Omae T, Reid J, Safar M. The 1993 guidelines for the management of mild hypertension: Memorandum from a WHO-ISH meeting. Blood Press 1993; 2: 86-100. (Pubitemid 23283623)
6. Guidelines Sub-Committee. 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. Blood Press 1999; 8 (suppl 1): 9-43.
7. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Ménard J, Julius S, Rahn KH, Wedel H, Westerling S for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762. (Pubitemid 28269185)
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
9. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-795.
10. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-59. (Pubitemid 28137527)
11. Malmqvist K. In hypertensive women candesartan cilexetil lowers blood pressure more and causes less adverse events compared to enalapril and hydrochlorothiazide: the CANDHY-2 Study. International Forum on Angiotensin II Receptor Antagonism, Monte Carlo, January 26-30, 1999 (Poster).
12. Chalmers J. Personal view: The national consensus conference - not always what it seems. Blood Press 1994; 3: 4-6. (Pubitemid 24089506)
13. Hansson L, Hedner T, Jern S. After SHEP, STOP and MRC - New WHO/ISH guidelines for the management of mild hypertension. Blood Press 1993; 2: 83-84. (Pubitemid 23283622)
14. Anonymous. The hidden epidemic of cardiovascular disease (editorial). Lancet 1998; 352: 1795.